300142 沃森生物
午间休市 03-20 11:30:00
资讯
新帖
简况
控制权变更！300142，前“福建首富”将入主！明天复牌
e公司 · 03-18 20:49
控制权变更！300142，前“福建首富”将入主！明天复牌
沃森生物最新公告：控股股东将变更为腾云新沃明起复牌
证券之星 · 03-18 18:41
沃森生物最新公告：控股股东将变更为腾云新沃明起复牌
沃森生物拟非公开发行A股募资不超过20亿元，补充营运资金
美股速递 · 03-18 18:38
沃森生物拟非公开发行A股募资不超过20亿元，补充营运资金
沃森生物(300142.SZ)筹划公司控制权变更事项 3月17日起停牌
智通财经 · 03-16
沃森生物(300142.SZ)筹划公司控制权变更事项 3月17日起停牌
沃森生物公告：因潜在控股权变动，公司股票自3月17日起停牌
美股速递 · 03-16
沃森生物公告：因潜在控股权变动，公司股票自3月17日起停牌
沃森生物最新公告：子公司签署海外市场战略合作协议
证券之星 · 03-13
沃森生物最新公告：子公司签署海外市场战略合作协议
沃森生物：公司高管团队有明确的职责分工
证券之星 · 03-11
沃森生物：公司高管团队有明确的职责分工
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 03-10
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物(300142.SZ)：吸附破伤风疫苗进入Ⅲ期临床试验
智通财经网 · 03-06
沃森生物(300142.SZ)：吸附破伤风疫苗进入Ⅲ期临床试验
沃森生物：持续探索绿色低碳发展之路
证券之星 · 03-06
沃森生物：持续探索绿色低碳发展之路
沃森生物：公司将根据自身实际情况，充分利用各项政策，不断推进相关产品和项目的进度
证券之星 · 03-03
沃森生物：公司将根据自身实际情况，充分利用各项政策，不断推进相关产品和项目的进度
沃森生物：两个在研产品分别于2025年10月和12月获得临床试验批准通知书
证券之星 · 03-02
沃森生物：两个在研产品分别于2025年10月和12月获得临床试验批准通知书
沃森生物：公司与相关方共同发起设立云南创沃生物产业投资基金
证券之星 · 02-27
沃森生物：公司与相关方共同发起设立云南创沃生物产业投资基金
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 02-27
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物：目前为天然藻源
证券之星 · 02-26
沃森生物：目前为天然藻源
沃森生物：公司20价肺炎球菌多糖结合疫苗目前处于I期临床试验的准备阶段
证券之星 · 02-12
沃森生物：公司20价肺炎球菌多糖结合疫苗目前处于I期临床试验的准备阶段
沃森生物：公司将严格按照相关法律法规和药监部门的相关规定进行分类
证券之星 · 02-12
沃森生物：公司将严格按照相关法律法规和药监部门的相关规定进行分类
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
21世纪经济报道 · 02-12
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
沃森生物(300142.SZ)拟出资4.5亿元发起设立云南创沃生物产业投资基金
智通财经 · 02-11
沃森生物(300142.SZ)拟出资4.5亿元发起设立云南创沃生物产业投资基金
沃森生物最新公告：公司水痘减毒活疫苗获临床试验批准
证券之星 · 02-10
沃森生物最新公告：公司水痘减毒活疫苗获临床试验批准
加载更多
公司概况
公司名称：
云南沃森生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2010-11-12
主营业务：
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是人用疫苗。
发行价格：
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":12.43,"timestamp":1773978618000,"preClose":12.39,"halted":0,"volume":45864270,"delay":0,"changeRate":0.0032,"floatShares":1556000000,"shares":1599000000,"eps":0.0308,"marketStatus":"午间休市","change":0.04,"latestTime":"03-20 11:30:00","open":12.25,"high":12.8,"low":12.23,"amount":574000000,"amplitude":0.046,"askPrice":12.43,"askSize":577,"bidPrice":12.42,"bidSize":1467,"shortable":0,"etf":0,"ttmEps":0.0308,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773982800000},"marketStatusCode":3,"adr":0,"adjPreClose":12.39,"symbolType":"stock","openAndCloseTimeList":[[1773970200000,1773977400000],[1773982800000,1773990000000]],"highLimit":13.63,"lowLimit":11.15,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":2.05,"roa":"--","peRate":403.571429,"roe":"1.72%","epsLYR":0.0889,"committee":0.165896,"marketValue":19880000000,"turnoverRate":0.0295,"status":0,"floatMarketCap":19340000000},"requestUrl":"/m/hq/s/300142","defaultTab":"news","newsList":[{"id":"2620620256","title":"控制权变更！300142，前“福建首富”将入主！明天复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620620256","media":"e公司","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620620256?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:49","pubTimestamp":1773838140,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 沃森生物股票3月19日开市起复牌。公司首任实控人将要揭晓。 上市近16年，沃森生物将迎来首任实控人，背后有意斥资近20亿元入主上市公司的资本方，来自知名闽商黄如论、黄涛家族。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-03-18/doc-inhrmpqp9198529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0077","BK0239","BK0070","300142","BK0046"],"gpt_icon":0},{"id":"2620323211","title":"沃森生物最新公告：控股股东将变更为腾云新沃明起复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620323211","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620323211?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:41","pubTimestamp":1773830483,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司正筹划向腾云新沃发行股票，发行价格9.63元/股，募集资金总额不超过20.03亿元，扣除发行费用后全部用于补充流动资金。发行后，腾云新沃持股11.51%，与其一致行动人合计持股14.46%，公司控股股东将变更为腾云新沃，实际控制人变更为黄涛。公司股票自3月19日开市起复牌。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800033540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0070","BK0239","BK0077","BK0046"],"gpt_icon":0},{"id":"1104710629","title":"沃森生物拟非公开发行A股募资不超过20亿元，补充营运资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1104710629","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104710629?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:38","pubTimestamp":1773830305,"startTime":"0","endTime":"0","summary":"沃森生物今日宣布，公司计划通过非公开发行A股股票的方式，募集资金总额不超过人民币20亿元，所募资金将主要用于补充公司营运资金及优化财务结构。此次非公开发行对象为不超过35名特定投资者，发行价格不低于定价基准日前20个交易日公司股票交易均价的80%。截至今日收盘，沃森生物股价报收XX元，当日涨跌幅XX%。本次非公开发行方案尚需公司股东大会审议通过及深交所审核、中国证监会注册后方可实施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0077","BK0070","300142","BK0239"],"gpt_icon":0},{"id":"2619157455","title":"沃森生物(300142.SZ)筹划公司控制权变更事项 3月17日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2619157455","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619157455?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:00","pubTimestamp":1773651637,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物(300142.SZ)发布公告，公司正在筹划向特定对象发行A股股票，该事项可能会导致公司控制权发生变更。目前，各方主体正在就具体方案、协议等相关事项进行论证和磋商，具体情况以各方最终签署的相关协议为准。经公司向深圳证券交易所申请，公司股票自2026年3月17日(星期二)开市起停牌，预计停牌时间不超过2个交易日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300142","BK0046","BK0070","BK0077","BK0239"],"gpt_icon":0},{"id":"1148460144","title":"沃森生物公告：因潜在控股权变动，公司股票自3月17日起停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1148460144","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148460144?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:52","pubTimestamp":1773651132,"startTime":"0","endTime":"0","summary":"沃森生物（300142）发布公告称，因公司可能发生控股权变更的重大事项，为维护投资者利益并确保信息公平披露，公司股票自2024年3月17日开市起停牌。待相关事项确定后，公司将及时发布进展公告并申请复牌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0077","BK0070","300142","BK0239"],"gpt_icon":0},{"id":"2619686199","title":"沃森生物最新公告：子公司签署海外市场战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2619686199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619686199?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:01","pubTimestamp":1773399677,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司全资子公司香港沃森近日与江苏中慧元通生物科技股份有限公司（简称“中慧元通”）签署了《海外市场战略合作协议》，就双方进行海外市场战略合作达成一致。双方同意，中慧元通及其附属公司指定香港沃森（或香港沃森指定的关联方）为疫苗产品（指由中慧元通生产的三价流感病毒亚单位疫苗）在区域（指除菲律宾、澳门以外的其他地域，包括公立和私立市场）内的国际业务开发排他的合作伙伴，负责疫苗产品与区域内的注册（含可能需要的当地临床试验）、推广及销售。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300033450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","BK0046","BK0239","300142"],"gpt_icon":0},{"id":"2618980129","title":"沃森生物：公司高管团队有明确的职责分工","url":"https://stock-news.laohu8.com/highlight/detail?id=2618980129","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618980129?lang=zh_cn&edition=full","pubTime":"2026-03-11 08:27","pubTimestamp":1773188823,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2026年董事会换届已完成，新当选非独立董事具备国药集团背景，且组织架构已完成精简优化。请问换届后高管团队的核心分工是否明确，国药体系的产业资源、渠道资源已落地哪些具体合作？本次组织架构调整，公司高管团队有明确的职责分工。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100007251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","300142","BK0046","BK0070"],"gpt_icon":0},{"id":"2618815987","title":"沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2618815987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618815987?lang=zh_cn&edition=full","pubTime":"2026-03-10 15:54","pubTimestamp":1773129247,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物03月10日在投资者关系平台上答复投资者关心的问题。公司九价HPV疫苗目前处于III期临床研究阶段。公司严格按照创业板行业信息披露等有关法规和规范性文件的规定披露公司在研产品的研发进展信息，公司在研疫苗的研发若有实质性和阶段性进展公司将及时披露，相关产品的后续进展情况请持续关注公司披露的信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000021463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","159646","BK0239","BK0046","BK0070","300142"],"gpt_icon":0},{"id":"2617068544","title":"沃森生物(300142.SZ)：吸附破伤风疫苗进入Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2617068544","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617068544?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:03","pubTimestamp":1772787811,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物(300142.SZ)公告，公司和子公司玉溪沃森生物技术有限公司自主研发的吸附破伤风疫苗，于2024年11月获得《药物临床试验批准通知书》，2025年8月收到临床试验机构伦理审查委员会出具的《伦理审查意见书》，于近期完成Ⅰ期临床试验阶段现场主要研究工作，目前已进入Ⅲ期临床试验阶段。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"沃森生物(300142.SZ)：吸附破伤风疫苗进入Ⅲ期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159646","BK0077","BK0070","300142","BK0046","BK0239"],"gpt_icon":0},{"id":"2617688815","title":"沃森生物：持续探索绿色低碳发展之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2617688815","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617688815?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:48","pubTimestamp":1772783289,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物03月06日在投资者关系平台上答复投资者关心的问题。公司遵循《国际财务报告可持续披露准则第 2 号—气候相关披露》《深圳证券交易所上市公司自律监管指引第 17 号—可持续发展报告（试行）》的框架建议，持续探索绿色低碳发展之路，提升气候风险应对能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600021292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","399258","BK0077","BK0239","BK0046","BK0070"],"gpt_icon":0},{"id":"2616340525","title":"沃森生物：公司将根据自身实际情况，充分利用各项政策，不断推进相关产品和项目的进度","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340525","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616340525?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:51","pubTimestamp":1772542281,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)03月02日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司对155我生物制造这块有何规划沃森生物回复：尊敬的投资者，您好！国家鼓励生物医药、生物制造产业发展并出台了一系列的扶持政策，公司将根据自身实际情况，充分利用各项政策，不断推进相关产品和项目的进度。关于公司相关产品和项目的后续情况请持续关注公司披露的信息。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300041987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0077","BK0070","BK0239","BK0046"],"gpt_icon":0},{"id":"2616385879","title":"沃森生物：两个在研产品分别于2025年10月和12月获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616385879","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616385879?lang=zh_cn&edition=full","pubTime":"2026-03-02 15:18","pubTimestamp":1772435903,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物03月02日在投资者关系平台上答复投资者关心的问题。2026 年是否有明确的 IND 申报或 Ⅰ 期临床启动计划？您所提到的两个在研产品公司分别于2025年10月和12月获得临床试验批准通知书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200015140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0070","BK0239","BK0077","BK0046"],"gpt_icon":0},{"id":"2614838136","title":"沃森生物：公司与相关方共同发起设立云南创沃生物产业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2614838136","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614838136?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:48","pubTimestamp":1772182101,"startTime":"0","endTime":"0","summary":"公司于2026年2月10日召开第六届董事会第二次会议，审议通过了公司与相关方共同发起设立云南创沃生物产业投资基金，基金目标规模为10亿元，其中，公司以自有资金出资4.5亿元，为有限合伙人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700027008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0070","300142","BK0046"],"gpt_icon":0},{"id":"2614171838","title":"沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2614171838","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614171838?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:42","pubTimestamp":1772181724,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)02月27日在投资者关系平台上答复投资者关心的问题。投资者提问：九价 HPV 疫苗 Ⅲ 期临床是否已完成全部病例随访？若已完成，总结报告预计何时出具？申报 NDA 的时间窗口是否在 2026 年 Q2？申报前是否需补充临床数据沃森生物回复：尊敬的投资者，您好！公司九价HPV疫苗目前处于III期临床研究阶段，公司在研疫苗的研发若有实质性和阶段性进展公司会及时披露，后续进展情况请关注公司披露的相关信息。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700026805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","300142","BK0046","BK0070","159646"],"gpt_icon":0},{"id":"2614094706","title":"沃森生物：目前为天然藻源","url":"https://stock-news.laohu8.com/highlight/detail?id=2614094706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614094706?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:07","pubTimestamp":1772089633,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司旗下爱森泽生物的虾青素，是天然藻源还是化学合成？技术路线是什么？当前虾青素原料市场涨价明显，公司是否有提价计划、产能规划及成本控制措施？谢谢。沃森生物回复：尊敬的投资者，您好！目前为天然藻源。关于相关产品和项目的后续情况请持续关注公司披露的信息。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600016803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300142","BK0077","BK0046","BK0070"],"gpt_icon":0},{"id":"2610992817","title":"沃森生物：公司20价肺炎球菌多糖结合疫苗目前处于I期临床试验的准备阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992817","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610992817?lang=zh_cn&edition=full","pubTime":"2026-02-12 11:35","pubTimestamp":1770867309,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物02月11日在投资者关系平台上答复投资者关心的问题。mRNA 管线：公司 mRNA 带状疱疹、RSV 疫苗已获临床批件，目前临床 I/II 期进展是否超预期？预计何时进入关键临床阶段？公司20价肺炎球菌多糖结合疫苗目前处于I期临床试验的准备阶段，将按照国家对于注册临床试验的有关程序和要求积极推进。关于20价肺炎结合疫苗的保护效力须以效力临床试验的最终结果为准，请持续关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200014477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","300142","BK0077","BK0070","BK0239","BK0046"],"gpt_icon":0},{"id":"2610992844","title":"沃森生物：公司将严格按照相关法律法规和药监部门的相关规定进行分类","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610992844?lang=zh_cn&edition=full","pubTime":"2026-02-12 11:34","pubTimestamp":1770867286,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物02月11日在投资者关系平台上答复投资者关心的问题。投资者提问：玉溪沃森的2025年公司接受各级管辖部门检查和处罚情况还是没有更新，请问下何时进行更新？？沃森生物官网上双价HPV还列入到非免疫规划里面去了。。关于免疫规划疫苗和非免疫规划疫苗的划分，公司将严格按照相关法律法规和药监部门的相关规定进行分类，感谢您对公司提出的宝贵意见和建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200014443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","300142","BK0070","BK0239"],"gpt_icon":0},{"id":"2610960339","title":"新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960339","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960339?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:27","pubTimestamp":1770852424,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委等11部门联合印发《国家基本药物目录管理办法》2月11日，国家卫生健康委等联合印发《国家基本药物目录管理办法》。与原有的文件相比，《国家基本药物目录管理办法》主要修订六个方面：一是增加法律政策依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123648366353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123648366353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1580142542.USD","LU1781817850.SGD","301075","BK0077","BK0099","LU2580892862.HKD","LU1328615791.USD","LU1997245177.USD","600276","LU1064131003.USD","LU0405327494.USD","BK0097","300683","BK0070","LU2289578879.USD","BK0183","LU2097828631.EUR","BK0060","BK0028","LU2097828557.USD","LU0405327148.USD","LU1064130708.USD","LU2148510915.USD","LU2580892789.USD","LU1969619763.USD","BK0175","BK0188","LU2097828714.EUR","BK0046","BK0012","601607","300142","BK0209","BK0239","LU1255011170.USD","LU1820825898.SGD","BK0184","LU2097828474.EUR","LU1997245094.SGD","LU1997244956.HKD","LU2328871848.SGD","BK0187","BK0020","LU2097828805.USD","LU2495084118.USD","LU2488822045.USD","BK0196","LU1146622755.USD","LU1655091616.SGD"],"gpt_icon":0},{"id":"2610987141","title":"沃森生物(300142.SZ)拟出资4.5亿元发起设立云南创沃生物产业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2610987141","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610987141?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:05","pubTimestamp":1770800708,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物 发布公告，2026年2月10日，公司召开第六届董事会第二次会议，审议通过了《关于与专业投资机构共同投资并签署<云南创沃生物产业投资基金合伙企业合伙协议>的议案》。根据协议约定，云南创沃生物产业投资基金核心投资方向聚焦合成生物学、生物制造及生物技术相关产业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0046","BK0239","300142","BK0070"],"gpt_icon":0},{"id":"2610364643","title":"沃森生物最新公告：公司水痘减毒活疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2610364643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610364643?lang=zh_cn&edition=full","pubTime":"2026-02-10 18:40","pubTimestamp":1770720036,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司及子公司联合研发的水痘减毒活疫苗获国家药品监督管理局签发的《药物临床试验批准通知书》。该疫苗采用水痘-带状疱疹病毒减毒株接种人二倍体细胞制成，用于预防水痘。目前国内已有六家企业的水痘减毒活疫苗获批上市许可。该疫苗获批进入临床试验，对公司本年度业绩不会产生大的影响，后续还需进行确证性III期临床试验并申请药品上市许可，期间存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000032255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","BK0239","BK0077","300142"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773978635662,"stockEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":0.0342},{"period":"3month","weight":0.0993},{"period":"6month","weight":0.0421},{"period":"1year","weight":0.0406},{"period":"ytd","weight":0.1386}],"compareEarnings":[{"period":"1week","weight":-0.0297},{"period":"1month","weight":-0.0185},{"period":"3month","weight":0.0298},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.1693},{"period":"ytd","weight":0.0095}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"114040人(较上一季度减少2.75%)","perCapita":"13643股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是人用疫苗。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}